
Claritev Corporation (CTEV) Market Cap
Claritev Corporation has a market capitalization of $387.2M.
Price: $22.71
▼ -0.87 (-3.69%)
Market Cap: 387.16M
NYSE · time unavailable
CEO: Travis S. Dalton
Sector: Healthcare
Industry: Medical - Healthcare Information Services
IPO Date: 2020-04-03
Website: https://www.claritev.com
Claritev Corporation (CTEV) - Company Information
Market Cap: 387.16M|Sector: Healthcare
Company Profile
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.
Analyst Sentiment
From 6 Active Polls
1Y Forecast: $38.80
▲ +70.8% Potential Upside
Consensus Target Metrics
Low Bound
$28
Median
$37
High Bound
$61
Average
$39
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
📊 Historical Valuation Multiples
Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.
| Fiscal Quarter | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Period Ending | Trailing 12M | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Market Cap ($M) | 387 | 273 | 703 | 875 | 743 | 336 | 472 | 471 | 471 |
| Enterprise Value ($M) | 4,975 | 4,860 | 5,318 | 5,477 | 5,336 | 4,944 | 4,996 | 4,923 | 4,965 |
| Price to Earnings Ratio (P/E) | -1.31 | -0.93 | -2.19 | -3.14 | -2.96 | -1.18 | -0.86 | -0.30 | -0.20 |
| Price/Earnings-to-Growth Ratio (PEG) | — | — | -9.05 | -1.73 | -0.67 | — | -1.20 | — | — |
| Price to Sales Ratio (P/S) | 0.40 | 1.11 | 2.85 | 3.56 | 3.07 | 1.45 | 2.03 | 2.05 | 2.02 |
| Price to Book Ratio (P/B) | -1.57 | -1.13 | -4.04 | -8.59 | -18.61 | 22.64 | 5.61 | 2.27 | 0.78 |
| Price to Free Cash Flow Ratio (P/FCF) | -10.78 | -2.95 | 19.31 | -53.52 | 20.28 | -4.87 | -7.31 | 11.46 | -67.48 |
| Enterprise Value to Sales (EV/Sales) | — | 19.86 | 21.57 | 22.27 | 22.09 | 21.37 | 21.52 | 21.36 | 21.27 |
| Enterprise Value to EBITDA (EV/EBITDA) | 9.61 | 41.60 | 50.76 | 32.79 | 41.42 | 43.64 | 1020.40 | -21.66 | -11.99 |
| Debt to Equity Ratio | 8.87 | -19.11 | -26.64 | -45.69 | -116.50 | 312.43 | 54.05 | 21.86 | 7.53 |
📰 Market News & Coverage
15 Stories AvailableReal-time institutional reporting and market updates for CTEV.
Related Companies in Healthcare
📊 AI Financial Analysis
Powered by StockMarketInfo"CTEV reported Q1’26 revenue of $244.7M, up 0.9% QoQ (vs. $246.6M in Q4’25) and up 5.8% YoY (vs. $231.3M in Q1’25). Net income was -$73.6M (EPS -$4.41), improving vs. -$80.6M in Q4’25 and vs. -$71.3M in Q1’25 (YoY deterioration: net income down ~3.2%; losses widened). Profitability is highly volatile across the last four quarters: operating margin was 2.7% in Q1’26 (vs. 3.5% Q4’25 and 4.2% Q1’25), while net margin remained deeply negative at -30.1%. The primary pressure remains below-the-line items (income before tax -$73.6M) rather than revenue growth itself. Cash flow quality weakened sequentially: operating cash flow was -$45.8M in Q1’26 (vs. +$66.3M in Q4’25), driving free cash flow to -$92.5M. Balance sheet leverage looks strained with total assets $4.84B and negative total equity of about -$234M; long-term debt remains very large (~$4.59B), and cash dropped to ~$21M. Shareholder returns appear muted/negative on momentum: price is $20.59 with only +1.33% 1-year change and no dividend. With no buyback disclosed in Q1’26, total shareholder return looks largely driven by lack of positive price momentum."
Revenue Growth
Revenue was $244.7M in Q1’26, up ~0.9% QoQ and ~5.8% YoY, indicating modest underlying topline growth but not an accelerating trend.
Profitability
Margins remain weak: net margin was -30.1% in Q1’26, and operating margin eased to 2.7% (vs. 3.5% in Q4’25). Net losses persisted despite positive YoY revenue.
Cash Flow Quality
Operating cash flow turned negative in Q1’26 (-$45.8M) after strongly positive Q4’25 (+$66.3M), with free cash flow at -$92.5M. No dividends and limited evidence of shareholder cash returns.
Leverage & Balance Sheet
Balance sheet resilience is pressured: total assets ~ $4.84B but total equity is negative (~ -$234M). Long-term debt remains ~ $4.59B and net debt is very high (~$4.59B).
Shareholder Returns
Stock momentum is not strong (+1.33% 1Y, -63.6% 6M). No dividend disclosed; buybacks not evident in Q1’26, limiting total return.
Analyst Sentiment & Valuation
Price target consensus ($32; high $38/low $28) implies potential upside vs. $20.59, but valuation support is undermined by persistent losses, negative equity, and recent cash flow deterioration.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Fundamentals Overview
CTEV delivered a strong Q1 2026 beat with revenue of $244.7M (+5.8% YoY) and adjusted EBITDA of $146.9M (+3.4% YoY) at ~60% margin, alongside record $44.1M ACV bookings toward a $80M-$100M target. Management’s edge is attributed to scaled data rights and workflow automation amplified by AI: provider-contact ID generation cut processing time by >50% and saved >2,000 hours; invoice automation for accounts payable IDR runs thousands of invoices/day with nearly 100% accuracy. Near-term margin pressure appears limited; investment started in Q4 and is expected to be ratable, with stable-to-improving margins in 2H as ACV converts (6-12 month lag). Guidance was raised: revenue to $985M-$1B; full-year adjusted EBITDA held at $605M-$615M (61%-62% margins). Demand headwinds (PSAV volume decline and MA rule changes) were framed as largely offset by acuity/rate mix and minimal quarterly volume impact, keeping the outlook constructive.
Growth Catalysts
- Data iSight (reference-based pricing) outperformed, up 8.4% in Q1 within claims intelligence
- Higher-acuity outpatient mix drove ~80% of identified savings/revenue in claims analytics (incl. behavioral health)
- Automation of provider-contact ID (saved >2,000 processing hours) and AI invoice extraction/reconciliation for accounts payable IDR (nearly 100% accuracy, automated 100% daily processing in <1 hour)
- Services business launch gaining foothold in provider and public sector markets via managed services
Business Development
- Agreement with GDIT to provide a custom network for the World Trade Center Health Program
- Signed a relationship with a top-5 health system operating >700 facilities; services include managed services for its EMR, enabled by the Q4 acquisition of OPCG
- Dallas Scrip added late in 2025 to drive TPA market expansion (AI throughout TPA client life cycle background)
Financial Highlights
- Total revenue: $244.7M, up 5.8% YoY (Q1 outperformed internal expectations)
- Adjusted EBITDA: $146.9M, up 3.4% YoY at ~60% margin
- Unlevered free cash flow: $36.8M, up 181% (+$23.7M); free cash flow use: $92.5M (lower by $23.6M vs prior year)
- Bookings: $44.1M ACV in Q1 toward $80M-$100M full-year target (already ~halfway)
- Q1 bookings mix: 73% cross-sell/upsell, 27% net new clients; closed 19 deals >$100k ACV and 9 deals >$1M ACV (350% increase in 7-figure deals)
- Guidance raise: revenue range increased to $985M-$1.0B (bottom end +$5M)
- Full-year adjusted EBITDA guidance maintained at $605M-$615M with margins of 61%-62%
Capital Funding
- Capital budget maintained at $160M-$170M for 2026
- Positive free cash flow expected; cash conversion expected to normalize to pre-2025 levels by end of year
- No buyback amounts, new debt levels, or explicit cash runway figures stated in transcript
Strategy & Ops
- AI coding tools nearly doubled engineering coding capacity without increased headcount (operating leverage)
- Expected investment spend ratable quarter-to-quarter after starting in Q4; guidance implies stable-to-slightly improving margins in back half
- PSAV: modest volume declines in Q1 offset by favorable rate mix; business characterized as more mixed/acuity-driven with growth in complex/higher-cost claims vs more claims volume
- Utilization: no quarter-to-quarter disruption from weather events; any observed volume softness described as less than expected but savings/revenue per claim strong
Market Outlook
- ACV sales target for 2026: $80M-$100M (20%-50% increase vs prior year); expectation that remaining conversion supports continued strong bookings momentum
- Full-year revenue: $985M-$1.0B (Q2 expected relatively flat sequentially); second-half growth rate expected at 3%-5%
- Adjusted EBITDA: $605M-$615M; margins 61%-62%
- Revenue conversion timing: new bookings take 6-12 months to convert to revenue; ACV ramps expected to drive more in 2H with broader revenue impact in 2027
Risks & Headwinds
- PSAV exposure: 8% YoY PSAV claims volume decline referenced by analyst; management states growth driven by acuity/rate mix and AI-driven savings rather than volume
- Medicare Advantage (MA) final rule: management indicated limited/near-zero quarter-to-quarter volume impact (close to 0 volume impact) despite changes to inpatient determinations and concurrent review cadence
- Potential demand cyclicality in core: services provide earlier/recurring revenue benefit, implying core seasonality could otherwise affect near-term conversion
Q&A: Analyst Interest
- Margin drivers: Management explained Q4 began investing to support ACV growth; annualized adjusted OpEx run-rate ~ $385M. They slightly outperformed revenue/EBITDA internally, expect investment to be ratable with ~$1M-$2M quarter swings, and margin stability/slight improvement in 2H as ACV converts.
- Utilization and rate/mix: Management cited slide-based outpatient/inpatient dynamics: possibly slightly less volume than expected, but strong savings, identified savings/revenue, and savings per claim. Elevated higher-acuity outpatient trends drive ~80% of identified savings/revenue; behavioral health remained consistently strong with no weather-driven disruption indicated.
- Medicare Advantage and PSAV volume: Management responded that MA could become an opportunity mid/long term but should have limited impact quarter-to-quarter; they expect close to 0 volume impact. For PSAV, they highlighted 8% YoY claims volume decline was expected to be offset by rate mix and AI-enabled savings extraction.
Sentiment: POSITIVE
Note: This summary was synthesized by AI from the CTEV Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.
📋 Official Regulatory 10-K / 10-Q SEC Filings
Direct authenticated documentation links to audited SEC database reports for CTEV.




















